Case Report: Treatment of Major Aphthous Lesions of Behçet’s Disease with Immunomodulatory Effects of Low-Dose Antibiotic Treatment

Year 2023, Volume: 1 Issue: 1, 20 - 22, 30.04.2023

Arda Özgön , Meltem Koray

Abstract

Aim: Behçet’s disease (BD) is a multisystemic inflammatory disease. The most common symptoms are recurrent major aphthous lesions in mouth. It is the initial symptom in most (about 80%) of the cases. It is very crucial to treat oral symptoms in order to minimize oral discomfort caused by inflammatory lesions in BD patients. The aim of this case report is to ameliorate the oral symptoms of BD by using the immunomodulatory effects of antibiotics.
Case Report: We present treatment of BD’s oral symptoms by using the immunomodulatory effects of antibiotics. A 30-year-old patient presented to our clinic with 2 major aphthae and discomfort in eating. The patient was treated with low-dose azithromycin for 3 weeks.
Discussion: The low-dose antibiotic therapy is a proven treatment modality for relieving oral symptoms of BD. Low-dose azithromycin was successful in relieving the oral symptoms of BD within 3 weeks. In the treatment of advanced aphthous lesions, the completion of the healing in 3 weeks of treatment and the absence of recurrence of aphthous lesions in 2 months proves the success of the treatment.
Conclusion: One week after starting the treatment, improvement was observed in the lesions. After 3 weeks of treatment, the aphthous lesions were completely healed. It was observed that oral symptoms did not return at the end of the 2-month treatment follow-up. Although azithromycin is used in the treatment of aphthous lesions caused by BD, more research is needed in this area.

Keywords

Antibiotic, Azithromycin, Behçet’s disease, Low-dose antibiotic treatment, Surgery

References

• Yazici Y, Yurdakul S, Yazici H. Behçet’s syndrome. Curr Rheumatol Rep. 2010;12(6):429-435. doi:10.1007/s11926-010-0132-z
• Scherrer MAR, Rocha VB, Garcia LC. Behçet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92(4):452-464. doi:10.1590/abd1806-4841.20177359
• Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341(17):1284-1291. doi:10.1056/NEJM199910213411707
• Yurdakul S, Yazici H. Behçet’s syndrome. Best Pract Res Clin Rheumatol. 2008;22(5):793-809. doi:10.1016/j.berh.2008.08.005
• Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behçet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90(2):125-132. doi:10.1097/MD.0b013e318211bf28
• Dalvi SR, Yildirim R, Yazici Y. Behcet’s Syndrome. Drugs. 2012;72(17):2223-2241. doi:10.2165/11641370-000000000-00000
• Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis. 2014;5(3):112-134. doi:10.1177/2040622314523062
• Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620-632. doi:10.1111/1346-8138.13381
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510-1518. doi:10.1056/NEJMoa1408684
• Firth A, Prathapan P. Azithromycin: The First Broad-spectrum Therapeutic. Eur J Med Chem. 2020;207:112739. doi:10.1016/j.ejmech.2020.112739
• Van Braeckel E, van der Eerden MM. Long-term oral antibiotic treatment: why, what, when and to whom? In: Aliberti S, Chalmers JD, Pletz MW. ed. Anti-infectives and the lung. European Respiratory Society, Sheffield 2017: 185–205.
• Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol. 2013;169(5):1024-1034. doi:10.1111/bph.12187
• Pradhan S, Madke B, Kabra P, Singh AL. Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology. Indian J Dermatol. 2016;61(5):469-481. doi:10.4103/0019-5154.190105
• Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era?. Arch Med Res. 2005;36(6):697-705. doi:10.1016/j.arcmed.2005.06.009
• Becattini S, Taur Y, Pamer EG. Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol Med. 2016;22(6):458-478. doi:10.1016/j.molmed.2016.04.003
• Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107-118. doi:10.1016/j.cell.2005.05.007
• Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141. doi:10.1016/j.cell.2014.03.011
• Mumcu, G., Ergun, T., Elbir, Y., Eksioglu-Demiralp, E., Yavuz, S., Atalay, T., & Direskeneli, H. (2005). Clinical and immunological effects of azithromycin in Behcet’s disease. Journal of Oral Pathology and Medicine, 34(1), 13–16. doi:10.1111/j.1600-0714. 2004.00265.x